Hunan Siqi Biopharmaceutical Co., Ltd.

Hunan Jiuzhitang Siqi Biopharmaceutical Co., Ltd. is a key high-tech enterprise in Hunan Province and a key high-tech enterprise under the National Torch Program. With the sacred mission of "building health and happiness for mankind", the company is committed to the research and development, production and sales of biopharmaceuticals. Its flagship product, the national key new product "Siqikang" (scientific name: BCG Polysaccharide and Nucleic Acid Injection), is a biological immunomodulator that can effectively prevent and treat chronic bronchitis, colds, asthma and other diseases related to immune imbalance. Its annual sales exceed 100 million yuan. It was the first among similar products to pass national GMP certification, with a market share of 70%. It has won the "Hunan Province Product Quality Award" for three consecutive years and has been listed as a key project of the National Torch Program. Since its establishment in 1998, the company has achieved asset growth from 2 million yuan to 140 million yuan, created nearly 100 million yuan in profits and taxes, and was rated as a "Taxpayer of Over Ten Million Yuan Enterprise" by Changsha High-tech Development Zone for four consecutive years from 2000 to 2003. It has won the "Development Contribution Award" issued by Hunan Province key high-tech enterprise and Liuyang Biomedical Park, and ranks among the top ten in the national biopharmaceutical industry! The company has invested 80 million yuan in Liuyang Biomedical Park, Hunan, to build a modern production base that meets GMP requirements. It has established branches in 29 provinces, municipalities and autonomous regions across the country, and offices in more than 160 prefecture-level cities, and has established good commercial reputation and business cooperation relationships with 132 large and medium-sized pharmaceutical commercial companies and more than 3,200 hospitals of Grade II and above in China, and is gradually developing the international market. The company's human resource management mechanism of "carving dragons for dragons and phoenixes for phoenixes", scientific salary incentive mechanism and broad career space have attracted a large number of outstanding technical, management and marketing talents. The department heads of the company all have master's degrees or above, including 4 doctors, and employees with bachelor's degrees or above account for 60% of the total number of employees. The company attaches great importance to technological innovation, has formed an advisory group represented by national renowned experts such as Academician Zhong Nanshan and Academician Chen Hongduo, and has established extensive scientific research cooperation relationships with Guangzhou Medical College, China Medical University, Beijing Institute of Biological Products, etc., and invested 18 million yuan to develop high-tech biological products including genetically engineered drugs. The company will develop into a large-scale high-tech biopharmaceutical enterprise reaching international advanced standards within three to five years, strive to become the leader of China's biotechnology, and become a brilliant star in China's pharmaceutical industry.